Myriad Genetics Inc

NASDAQ:MYGNUnited States

Yesterday

Show headlines and story abstract

• Myriad Genetics, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - MYGN, from 16 hours ago by Dow Jones

  16 hours ago by Dow Jones
  Companies Mentioned: MYGN
  
  NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws.
  

• DJ Myriad Genetics in Active Talks with UnitedHealthcare to Keep Coverage of GeneSight, from 22 hours ago by Dow Jones

  22 hours ago by Dow Jones
  Companies Mentioned: MYGN
  
  By Sabela Ojea
  
  Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.
  

• Myriad Genetics Disputes Inclusion of GeneSight in UnitedHealthcare's Coverage Restriction, from 23 hours ago by MT Newswires

  23 hours ago by MT Newswires
  Companies Mentioned: MYGN
  10:56 AM EST, 11/04/2024 (MT Newswires) -- Myriad Genetics (MYGN) said Monday that it "strongly disagrees" with UnitedHealthcare's decision to restrict coverage access to multi-gene panel pharmacogenetic tests, including Myriad's GeneSight test, und...

• Myriad Genetics Comments on UnitedHealthcare's Updated Medical Policy for Pharmacogenetic Testing, from 8:39AM ET on Monday Nov 04, 2024 by Dow Jones

  8:39AM ET on Monday Nov 04, 2024 by Dow Jones
  Companies Mentioned: MYGN
  
  Myriad Genetics Comments on UnitedHealthcare's Updated Medical Policy for Pharmacogenetic Testing
  
  SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to multi-gene panel pharmacogenetic tests, including Myriad's GeneSight test, under its commercial and individual exchange benefit plans, effective January 1(st) , 2025.